PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

NOVAVAX to Present at the Lazard Capital Markets 8th Annual Healthcare Conference

ROCKVILLE, Md., Nov 10, 2011 (GlobeNewswire via COMTEX) --

Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Frederick W. Driscoll, Vice President and Chief Financial Officer of Novavax, will be presenting at the Lazard Capital Markets 8th Annual Healthcare Conference on November 15, 2011 at 3:30pm at The Pierre Hotel, New York City. A live audio-only webcast link for the presentation can be accessed via the Company website at www.novavax.com under Investors/Events.

About Novavax

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company's proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Novavax, Inc.

CONTACT: Frederick W. Driscoll
VP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000